Ocular Therapeutix Inc (NAS:OCUL)

$ 9.89 -0.17 (-1.69%) Market Cap: 1.55 Bil Enterprise Value: 1.20 Bil PE Ratio: 0 PB Ratio: 4.40 GF Score: 66/100

Q3 2024 Ocular Therapeutix Inc Earnings Call Transcript
Nov 14, 2024

$9.92 (-6.42%)

Earnings
Q2 2024 Ocular Therapeutix Inc Earnings Call Transcript
Aug 07, 2024

$8.37 (+6.08%)

Earnings
Q3 2023 Ocular Therapeutix Inc Earnings Call Transcript
Nov 07, 2023

$2.84 (+2.90%)

Earnings
Ocular Therapeutix Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 27, 2023
Q2 2023 Ocular Therapeutix Inc Earnings Call Transcript
Aug 07, 2023

$4.36 (-3.33%)

Earnings
Ocular Therapeutix Inc To Discuss the 12-Month Data Transcript
Jun 12, 2023
Ocular Therapeutix Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Ocular Therapeutix Inc at JMP Securities Life Sciences Conference Transcript
May 15, 2023
Q1 2023 Ocular Therapeutix Inc Earnings Call Transcript
May 08, 2023

$6.4 (+2.40%)

Earnings
Q4 2022 Ocular Therapeutix Inc Earnings Call Transcript
Mar 06, 2023

$5.58 (-5.58%)

Earnings
Ocular Therapeutix Inc To Discuss Interim Data Update Call Transcript
Feb 13, 2023
Q3 2022 Ocular Therapeutix Inc Earnings Call Transcript
Nov 07, 2022

$3.55 (+1.43%)

Earnings
Ocular Therapeutix Inc Corporate Call Transcript
Sep 27, 2022
Q2 2022 Ocular Therapeutix Inc Earnings Call Transcript
Aug 08, 2022

$5.06 (+2.02%)

Earnings
Q1 2022 Ocular Therapeutix Inc Earnings Call Transcript
May 09, 2022

$3.26 (-6.05%)

Earnings
Q4 2021 Ocular Therapeutix Inc Earnings Call Transcript
Feb 28, 2022

$5.58 (+1.09%)

Earnings
Ocular Therapeutix Inc to Discuss Results From Its Phase 2 Clinical Trial of OTX-DED Call Transcript
Dec 06, 2021
Q3 2021 Ocular Therapeutix Inc Earnings Call Transcript
Nov 08, 2021

$7.1 (+1.87%)

Earnings
Q2 2021 Ocular Therapeutix Inc Earnings Call Transcript
Aug 09, 2021

$10.73 (+1.90%)

Earnings
Q1 2021 Ocular Therapeutix Inc Earnings Call Transcript
May 05, 2021

$16.56 (-0.96%)

Earnings
Q4 2020 Ocular Therapeutix Inc Earnings Call Transcript
Mar 11, 2021

$20.31 (+3.31%)

Earnings
Ocular Therapeutix Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Q3 2020 Ocular Therapeutix Inc Earnings Call Transcript
Nov 05, 2020

$12 (-0.41%)

Earnings
Q2 2020 Ocular Therapeutix Inc Earnings Call Transcript
Aug 07, 2020

$8.21 (-2.96%)

Earnings
Ocular Therapeutix Inc Annual Shareholders Meeting Transcript
Jun 25, 2020
Q1 2020 Ocular Therapeutix Inc Earnings Call Transcript
May 08, 2020

$5.97 (-10.09%)

Earnings
Ocular Therapeutix Inc - Announces Results Of Phase 3 Clinical Trial of Dextenza Transcript
Apr 28, 2020
Q4 2019 Ocular Therapeutix Inc Earnings Call Transcript
Mar 12, 2020

$4.29 (-19.81%)

Earnings
Q3 2019 Ocular Therapeutix Inc Earnings Call Transcript
Nov 12, 2019

$2.57 (-12.29%)

Earnings
Q2 2019 Ocular Therapeutix Inc Earnings Call Transcript
Aug 07, 2019

$4.57 (-1.51%)

Earnings
Q1 2019 Ocular Therapeutix Inc Earnings Call Transcript
May 10, 2019

$3.68 (+0.55%)

Earnings
Ocular Therapeutix Inc Research & Development Day Transcript
Mar 28, 2019
Q4 2018 Ocular Therapeutix Inc Earnings Call Transcript
Mar 07, 2019

$4.38 (+1.86%)

Earnings

Ocular Therapeutix Inc To Discuss the 12-Month Data Transcript

Jun 12, 2023 / 12:30PM GMT

Release Date Price: $6.5 (-12.52%)

Transcript

Operator

Good day, and welcome to the Ocular Therapeutix conference call announcing 12-month data from the U.S.-based Phase I clinical trial evaluating OTX-TKI for the treatment of wet AMD.

(Operator Instructions)

As a reminder, this call may be recorded. I would now like to turn the call over to Antony Mattessich, Chief Executive Officer. You may begin.

Antony Mattessich

Ocular Therapeutix, Inc. - President, CEO & Director

Well, hello, and thanks for attending the Ocular Therapeutix press conference for our 12-week top line data or OTX-TKI. Let me start first by emphasizing how encouraged and excited we are with this data as it continues to support our product's profile and the potential to set the standard of care of durability in wet AMD, which is the highest unmet need in the space.

I'll be very brief and get directly to Dr. Arshad Khanani. Transitioning to Arshad is important not only because the he will be presenting the data, but also because Arshad is our largest enroller, has by far the most clinical experience treating

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.